Clinical trials: Seizures Disorders
Generalized Tonic Clonic Seizures
A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.
The study is designed to evaluate the safety, tolerability and efficacy of two doses of pregabalin as add-on treatment in pediatric and adult subjects with Primary Generalized Tonic-Clonic (PGTC) seizures as compared to placebo.
- Trial name
- NCT01747915
- Testing
- Pregabalin Dose Level 1, Pregabalin Dose Level 2
- Where
- 127 sites in United States, Austria and 24 more
- Volunteers
- 219 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Partial Epilepsies
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures
To evaluate the efficacy and safety of oral Lacosamide as first add on treatment in subjects with uncontrolled partial-onset seizures after prior treatment with a monotherapy Antiepileptic Drug (AED) regimen compared to subjects…
- Trial name
- NCT00955357
- Testing
- Lacosamide
- Where
- 109 sites in United States, Austria and 13 more
- Volunteers
- 461 people
- Sponsor
- UCB Pharma
Epilepsy, Partial-onset Seizures
Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures
EP0024 is a Phase 3, multicenter, open-label study to evaluate the safety and tolerability of intravenous (iv) lacosamide (LCM).
- Trial name
- NCT02192814
- Testing
- Lacosamide (200 mg/20 mL)
- Where
- 5 sites in Japan
- Volunteers
- 9 people
- Sponsor
- UCB Japan Co. Ltd.
Lennox-Gastaut Syndrome
A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)
To confirm that the combination therapy of rufinamide has superior efficacy compared to placebo in patients with Lennox-Gastaut syndrome.
- Trial name
- NCT01146951
- Testing
- Rufinamide (E2080)
- Where
- 23 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Eisai Limited
Anxiety Disorder, Seizures
Buspirone Therapy for Localized Epilepsy
Background: Buspirone is a drug that is approved for the treatment of anxiety in adults. Studies suggest that buspirone might act on parts of the brain that can increase certain levels of brain activity.
- Conditions
- Anxiety Disorder, Seizures, Epilepsy, Partial Epilepsy
- Trial name
- NCT01496612
- Testing
- Buspirone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Epilepsy; Seizure
Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy
This project studies how 2-deoxy-glucose (2DG) pills are absorbed and distributed in people with epilepsy. 2DG is similar to glucose, the main energy source for the brain, but it cannot be used as energy.
- Trial name
- NCT05605301
- Testing
- Oral 2-Deoxy-D-Glucose (2DG)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Virginia
Acute Repetitive Seizures
Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects
This study evaluates the pharmacokinetic and safety of NRL-1 in epilepsy subjects. Subjects will receive a single intranasal dose of NRL-1 of either 5 mg, 10 mg, 15 mg or 20 mg and will be based on the subject's body weight.
- Trial name
- NCT02724423
- Testing
- NRL-1
- Where
- 4 sites in United States
- Volunteers
- 57 people
- Sponsor
- Neurelis, Inc.
Tuberous Sclerosis Complex, Seizures
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P.
- Trial name
- NCT02544750
- Testing
- GWP42003-P
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Jazz Pharmaceuticals
Epilepsy, Non-Epileptic Seizure
Validation of Criteria for Identification of Epileptiform Discharges in EEG Recordings of Patients With Epilepsy
Electroencephalography (EEG) records electric activity of the brain using electrodes placed on the scalp. EEG is an important tool in the diagnostic work-up of patients with epilepsy.
- Trial name
- CIED (NCT03533374)
- Testing
- Electroencephalogram (EEG) and visual evaluation
- Volunteers
- 100 people
- Sponsor
- Sándor Beniczky
Post Stroke Epilepsy
Anti-epileptogenic Effects of Eslicarbazepine Acetate
This study aims to assess if eslicarbazepine acetate (ESL) treatment (started within 96 hours after stroke occurrence and continued for 30 days) changes the incidence of unprovoked seizures (USs) within the first 6 months after…
- Trial name
- NCT06597084
- Testing
- ESL 800 mg
- Where
- 22 sites in Austria, France and 7 more
- Volunteers
- 129 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy
Lamotrigine Extended-Release In Elderly Patients With Epilepsy
This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy. This study will be carried out using an extended-release formulation of lamotrigine (LTG-XR) that will…
- Trial name
- NCT00516139
- Testing
- Lamotrigine
- Where
- 63 sites in United States
- Volunteers
- 122 people
- Sponsor
- GlaxoSmithKline
Epilepsy
Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU
This study is designed to evaluate the efficacy, safety, and tolerability of USL261 compared with that of intranasal (IN) placebo for the treatment of intermittent bouts of increased seizure activity.
- Trial name
- NCT01999777
- Testing
- USL261
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 62 people
- Sponsor
- UCB Biopharma S.P.R.L.
Epilepsy, Partial Seizures
Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures
To demonstrate the non-inferiority of Levetiracetam (1000 mg/day) versus Carbamazepine Immediate-Release (400 mg/day) used as monotherapy for at least 6 months in a Chinese population with newly or recently diagnosed Epilepsy who…
- Trial name
- NCT01954121
- Testing
- Levetiracetam, Carbamazepine
- Where
- 28 sites in China
- Volunteers
- 436 people
- Sponsor
- UCB Pharma SA
Partial Onset Seizures
Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures
This study is designed to provide short term efficacy and safety data of TRI476 in children with inadequately-controlled partial seizures.
- Trial name
- NCT00975715
- Testing
- TRI476, Benzodiazepines
- Where
- 25 sites in Japan
- Volunteers
- 99 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder
Focal Electroconvulsive Therapy for Depression
This pilot, open label investigation evaluates the safety and efficacy of a new form of electroconvulsive therapy (ECT). Both the efficacy and adverse cognitive effects of ECT are highly contingent on the intracerebral current…
- Trial name
- FEAST (NCT01589315)
- Testing
- focal ECT
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Medical University of South Carolina
Partial Seizures
Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures
The objectives of this trial are to evaluate the safety and efficacy of Zonisamide as adjunctive therapy in medically refractory patients receiving other antiepileptic drugs (AEDs).
- Trial name
- NCT00327717
- Testing
- Zonisamide
- Where
- 8 sites in China
- Volunteers
- 240 people
- Sponsor
- Eisai Inc.
Epilepsy, Epilepsy, Generalized
Clobazam in Patients With Lennox-Gastaut Syndrome
The purpose of this study is to evaluate the safety and efficacy of clobazam as adjunctive therapy in the treatment of seizures which lead to drop attacks (drop seizures) in patients 2 to 60 years of age with Lennox-Gastaut…
- Conditions
- Epilepsy, Epilepsy, Generalized, Seizures
- Trial name
- NCT00518713
- Testing
- Clobazam Low Dose, Clobazam Medium Dose, Clobazam High Dose
- Where
- 53 sites in United States, Australia and 3 more
- Volunteers
- 238 people
- Sponsor
- Lundbeck LLC
Status Epilepticus, Convulsive Status EPILEPTICUS
Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus
This study will evaluate the effectiveness and safety of an investigational drug, IV ganaxolone, as adjunctive therapy to standard of care to treat subjects with status epilepticus.
- Conditions
- Status Epilepticus, Convulsive Status EPILEPTICUS, Non Convulsive Status Epilepticus, Epilepsy
- Trial name
- NCT03350035
- Testing
- IV Ganaxolone active
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- Marinus Pharmaceuticals
Partial Seizures With or Without Secondary Generalization, Epilepsy
A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
The purpose of the study is to evaluate the long-term safety and tolerability of Brivaracetam (BRV) in focal epilepsy subjects with partial seizures and to evaluate the maintenance of efficacy of BRV over time.
- Trial name
- NCT03250377
- Testing
- Brivaracetam
- Where
- 59 sites in China, Japan
- Volunteers
- 207 people
- Sponsor
- UCB Biopharma SRL
Epilepsy, Generalized Tonic-clonic Seizures
A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures
To evaluate the efficacy and safety of Levetiracetam dry syrup at doses up to 60 mg/kg/day or 3000 mg/day used as adjunctive therapy in Japanese pediatric patients aged ≥4 to <16 years with uncontrolled Generalized Tonic-Clonic…
- Trial name
- NCT01292837
- Testing
- Levetiracetam
- Where
- 26 sites in Japan
- Volunteers
- 13 people
- Sponsor
- UCB Japan Co. Ltd.